I do tend to disagree slightly with his opinion on satra...progression of pain was encompassed within the SPA's time to progression endpoint, so there is some, albeit limited, clinical significance. However, I completely agree with him that the convening of ODAC is Pazdur's dog and pony show to let PCa patients know that he is really a good guy. This NDA never would have had to go up before ODAC if he wasn't getting heat over the Provenge decision. The Phase III was right up Pazdur's alley: 950 patients, high degree of stat sig on a surrogate endpoint. In addition, the drug is right up Pazdur's alley as well: it's a platinum chemo drug with all sorts of nasty side effects, but not as nasty as Taxotere or even possibly other platinum chemos.
